Associate Professor School of Medicine

Yijin Wang, Ph.D., Associate Professor in the School of Medicine, Southern University of Science and Technology. After got the Master degree at Wageningen University and Research Center, the Netherlands, Yijin Wang moved to the Laboratory of Gastroenterology and Hepatology, Erasmus MC for her PhD research on Hepatitis E. She was concentrated on development of the anti-HEV therapies on the basis of understanding viral-host interaction. In addition to a list of publications, her discovery of potent antiviral activity by plants led to a Erasmus MC grant and harbour promising candidate for economical, less side-effect, complete anti-HEV therapy. Shortly after dissertation of PhD thesis in 2016, she started to establish her own research group at Department of Pathology and Hepatology, the 5thMedical Centre, Chinese people’s Liberation Army General Hospital, the best-known hospital specialized in infectious and liver diseases in China. As a young principal investigator, she supervised over 10 researchers. She has expended her research field to clinical and translational research of hepatitis B, C and E, SARS-CoV-2, as well as non-infectious liver diseases (NAFLD, HCC, ICC). By incorporating state-of-the-art molecular and cell biology, as well as abundant of patients specimen source, her research aims to contribute to the understanding of viral infection courses, virus-host interactions, mechanism of HEV activating and escaping innate immunity, to the development of new antiviral therapies and to resolving the clinical practical challenges. Dr. Wang’ group is already internationally well-recognized leader in respect of hepatitis E with significant contribution on viral infection biology, pathogenesis, and the development of accessible and effective antiviral therapy. Based on the research on infectious diseases, Dr. Wang also dedicated to elucidate novel mechanism of innate immune response. Her research has been supported by several (personal) grants, including “Science and Technology New Star" of BeiJing of 2019, National Natural Science Foundation of China, Innovative talent project of PLA General Hospital. She published 16 first /corresponding authorships (IF>170) of in total 38 publications in peer-reviewed international journal.

Personal Profile


1. Elucidating novel non-canonical mechanisms regulating innate immunity to form defence against viral infection, particularly based on nucleotide synthesis inhibition, mitochondrial function.

2. Understanding pathogenesis of hepatitis E on the basis of HEV viral infection courses, viral-host interaction, mechanisms of HEV activating and escaping innate immunity, and the antagonism to IFN therapy.

3. Development of potential economical, less side-effect anti-HEV strategy. Resolving the clinical practical challenges of hepatitis E, including diagnosis, diseases courses in distinct populations, prognosis and extra-hepatic manifestation.

4. Understand the spatial immune cell characteristics of hepatocellular carcinoma and cholangiocellular carcinoma, and explain the immunological mechanism of different prognosis of patients in various treatment methods via single cell and spatial transcriptome sequencing technology.

Publications Read More

  1. Li Y, Yu P, Kessler AL, Shu J, Liu X, Liang Z, et al. Hepatitis E virus infection activates NLRP3 inflammasome antagonizing interferon response but therapeutically targetable. Hepatology. 2021. (Co-Corresponding Author)
  2. Xu Z#, Shi L#, Wang Y#, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8:420-2. (Co-First Author)
  3. Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. Journal of hepatology. 2020; 73:807-16.
  4. Wang Y, Zhou X, Debing Y, Chen K, Van Der Laan LJ, Neyts J, et al. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology. 2014; 146:1775-83.
  5. Wang Y, Chen G, Pan Q, Zhao J. Chronic Hepatitis E in a Renal Transplant Recipient: The First Report of Genotype 4 Hepatitis E Virus Caused Chronic Infection in Organ Recipient. Gastroenterology. 2018; 154:1199-201.
  6. Wang Y#, Rao H#, Chi X#, Li B#, Liu H, Wu L, et al. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality. EBioMedicine. 2019; 46:227-35.
  7. Wang Y#, Wang S#, Wu J#, Jiang Y#, Zhang H, Li S, et al. Hepatitis E virus infection in acute non-traumatic neuropathy: A large prospective case-control study in China. EBioMedicine. 2018; 36:122-30. (First and Co-Corresponding Author)
  8. Wang Y#, Liu H#, Liu S#, Yang C, Jiang Y, Wang S, et al. Incidence, predictors and prognosis of genotype 4 hepatitis E related liver failure: A tertiary nested case-control study. Liver Int. 2019; 39:2291-300. (First and Co-Corresponding Author)
  9. Wang L, Wang Y*, Liu S, Zhai X, Zhou G, Lu F, et al. Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population. J Gastroenterol. 2019. (Co-Corresponding Author)
  10. Wang Y, Wang W, Xu L, Zhou X, Shokrollahi E, Felczak K, et al. Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication. Antimicrobial Agents and Chemotherapy. 2016; 60:2834-48.
  11. Wang Y, Liu H, Jiang Y, Pan Q, Zhao J. Poor Outcomes of Acute Hepatitis E in Patients With Cirrhotic Liver Diseases Regardless of Etiology. Open Forum Infect Dis. 2020; 7:ofaa107.
  12. Wang Y, Metselaar HJ, Peppelenbosch MP, Pan Q. Chronic hepatitis E in solid-organ transplantation: the key implications of immunosuppressants. Current Opinion in Infectious Diseases. 2014; 27:303-8.
  13. Wu J, Zhang X, Liu H, Guo N, Pan Q, Wang Y*. RDW, NLR and RLR in predicting liver failure and prognosis in patients with hepatitis E virus infection. Clinical Biochemistry. 2019; 63:24-31.(Corresponding Author)
  14. Wang Y, Liu S, Pan Q, Zhao J. Chronic hepatitis E in an immunocompetent patient. Clin Res Hepatol Gastroenterol. 2019.
  15. Gao Y#, Wang Y#, Liu H#, Liu Z, Zhao J. Mitochondrial DNA from hepatocytes induces upregulation of interleukin-33 expression of macrophages in nonalcoholicsteatohepatitis. Dig Liver Dis. 2020; 52:637-43.(Co-First Author)
  16. Li S#, Jiang L#, Li X#, Lin F#, Wang Y#, Li B, et al. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight. 2020; 5.(Co-First Author)
  17. Wang W, Wang Y, Qu C, Wang S, Zhou J, Cao W, et al. The RNA genome of hepatitis E virus robustly triggers an antiviral interferon response. Hepatology. 2018; 67:2096-112.
  18. Zhou X, Wang Y, Metselaar HJ, Janssen HL, Peppelenbosch MP, Pan Q. Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. Journal of Hepatology. 2014; 61:746-54.
  19. Wang W, Wang Y, Debing Y, Zhou X, Yin Y, Xu L, et al. Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication. Antiviral Research. 2017; 140:1-12.
  20. Yin Y, Wang Y, Dang W, Xu L, Su J, Zhou X, et al. Mycophenolic acid potently inhibits rotavirus infection with a high barrier to resistance development. Antiviral Research. 2016; 133:41-9.
  21. Zhou X, Xu L, Wang Y, Wang W, Sprengers D, Metselaar HJ, et al. Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication. Antiviral research. 2015; 124:11-9.
  22. Dang W, Yin Y, Wang Y, Wang W, Su J, Sprengers D, et al. Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication. Antimicrobial agents and chemotherapy. 2017; 61.
  23. Debing Y, Emerson SU, Wang Y, Pan Q, Balzarini J, Dallmeier K, et al. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrobial agents and chemotherapy. 2014; 58:267-73.
  24. Li M, Wang L, Wang Y, Zhang S, Zhou G, Lieshout R, et al. Mitochondrial Fusion Via OPA1 and MFN1 Supports Liver Tumor Cell Metabolism and Growth. Cells. 2020; 9.
  25. Zhang H, Rao H, Wang Y, Wang J, Kong X, Ji Y, et al. Evaluation of an antigen assay for diagnosing acute and chronic hepatitis E genotype 4 infection. Journal of gastroenterology and hepatology. 2019; 34:458-65.
  26. Zhang S, Qu C, Wang Y, Wang W, Ma Z, Peppelenbosch MP, et al. Conservation and variation of the hepatitis E virus ORF2 capsid protein. Gene. 2018; 675:157-64.
  27. Jiang L, Yang M, Li X, Wang Y, Zhou G, Zhao J. CXC Motif Ligand 16 Promotes Nonalcoholic Fatty Liver Disease Progression via Hepatocyte-Stellate Cell Crosstalk. The Journal of clinical endocrinology and metabolism. 2018; 103:3974-85.
  28. Yang M, Jiang L, Wang Y, Li X, Zou Z, Han T, et al. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease. J Gastrointestin Liver Dis. 2019; 28:289-96.
  29. Qu C, Zhang S, Li Y, Wang Y, Peppelenbosch MP, Pan Q. Mitochondria in the biology, pathogenesis, and treatment of hepatitis virus infections. Reviews in medical virology. 2019:e2075.
  30. Wang W, Yin Y, Xu L, Su J, Huang F, Wang Y, et al. Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections. Science signaling. 2017; 10.
  31. Xu L, Wang W, Li Y, Zhou X, Yin Y, Wang Y, et al. RIG-I is a key antiviral interferon-stimulated gene against hepatitis E virus regardless of interferon production. Hepatology. 2017; 65:1823-39.
  32. Xu L, Zhou X, Wang W, Wang Y, Yin Y, Laan LJ, et al. IFN regulatory factor 1 restricts hepatitis E virus replication by activating STAT1 to induce antiviral IFN-stimulated genes. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2016; 30:3352-67.
  33. Wang W, Xu L, Brandsma JH, Wang Y, Hakim MS, Zhou X, et al. Convergent Transcription of Interferon-stimulated Genes by TNF-alpha and IFN-alpha Augments Antiviral Activity against HCV and HEV. Scientific reports. 2016; 6:25482.
  34. Qu C, Zhang S, Wang W, Li M, Wang Y, van der Heijde-Mulder M, et al. Mitochondrial electron transport chain complex III sustains hepatitis E virus replication and represents an antiviral target. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2019; 33:1008-19.
  35. Zhou X, Xu L, Wang W, Watashi K, Wang Y, Sprengers D, et al. Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection. Journal of viral hepatitis. 2016; 23:294-304.
  36. Zhou X, Huang F, Xu L, Lin Z, de Vrij FMS, Ayo-Martin AC, et al. Hepatitis E Virus Infects Neurons and Brains. The Journal of infectious diseases. 2017; 215:1197-206.
  37. Yin Y, Bijvelds M, Dang W, Xu L, van der Eijk AA, Knipping K, et al. Modeling rotavirus infection and antiviral therapy using primary intestinal organoids. Antiviral research. 2015; 123:120-31.
  38. Hemachandra LP, Patel H, Chandrasena RE, Choi J, Piyankarage SC, Wang S, et al. SERMs attenuate estrogen-induced malignant transformation of human mammary epithelial cells by upregulating detoxification of oxidative metabolites. Cancer prevention research. 2014; 7:505-15.

Lab members Read More

Join us





  1. 年龄35岁以下,具备较高的学术水平和较强的科研能力的已获得博士学位的海内外优秀博士;
  2. 基础医学、生物化学、分子生物学、细胞生物学、免疫学相关专业;具备扎实的分子生物学研究基础,熟练掌握生物统计学分析方法和技巧;研究方向为病毒天然免疫、肿瘤发生机制;有大数据生物信息研究分析背景者优先;
  3. 具有良好的英文听说读写能力,能够独立撰写英文研究论文;以第一作者发表2篇以上SCI收录论文,至少1篇≥10分或JCR专业一区文章2篇以上;
  4. 能够独立开展科研工作,并协助指导研究生;
  5. 善于沟通和交流、责任心强、具有团队合作精神。


  1. 博士后聘用期两年,年薪33万元起,含广东省生活补助15万元及深圳市生活补助6万元,并按深圳市有关规定参加社会保险及住房公积金。博士后福利费参照学校教职工标准发放。
  2. 特别优秀候选人可以申请校长卓越博士后,年薪可达50万元以上。(含广东省及深圳市补助)。
  3. 在站期间,可依托学校申请深圳市公租房,未依托学校使用深圳市公租房的博士后,可享受两年税前2800元/月的住房补贴。
  4. 拥有优良的工作环境和境内外合作交流机会,博士后在站期间享受两年共计5万学术交流经费资助。
  5. 课题组协助符合条件的博士后申请“广东省海外青年博士后引进项目”。即在世界排名前200名的高校(不含境内,排名以上一年度泰晤士、USNEWS、QS和上海交通大学的世界大学排行榜为准)获得博士学位,在广东省博士后设站单位从事博士后研究,并承诺在站2年以上的博士后,申请成功后省财政给予每名进站博士后资助60万元生活补贴(与广东省每年15万生活补助不同时享受,与深圳市每年6万元生活补助同时享受情况以深圳市规定为准);对获得本项目资助,出站后与广东省用人单位签订工作协议或劳动合同,并承诺连续在粤工作3年以上的博士后,省财政给予每人40万元住房补贴。
  6. 博士后出站选择留深从事科研工作,且与本市企事业单位签订3年以上劳动(聘用)合同的,可以申请深圳市博士后留深来深科研资助。深圳市政府给予每人每年10万元科研资助,共资助3年(以深圳市最新申报要求为准)。
  7. 对于符合最新《深圳市新引进人才租房和生活补贴》相关政策要求的博士后,落户深圳后,可协助申请深圳市一次性租房和生活补贴3万元(免税,自主网上申请)。
  8. 依据自身符合的条件情况,在站或出站留深博士后可申请 "深圳市孔雀计划C类人才"或者"深圳市后备级人才",享受5年160万的奖励津贴(免税)(以深圳市最新相关人才申报要求为准)。


  1. 个人简历;
  2. 学历证书及获奖证书扫描件;
  3. 第一作者发表的SCI论文;
  4. 导师推荐信。


  1. 年龄35岁以下,基础医学、生物化学、分子生物学、细胞生物学、免疫学、生物信息学、流行病学相关专业硕士学位;
  2. 具有相对独立的科研能力,熟悉各种分子生物学实验操作,有分子信号通路研究经验优先,专业知识扎实,具备娴熟的实验设计和操作能力。
  3. 具有良好的英文听说读写能力,以第一作者发表过SCI论文。
  4. 热爱科研,工作努力;积极主动,认真细致负责;有良好的协调沟通能力与团队合作精神。心理及身体健康。


  1. 在PI带领下从事肿瘤或病毒的临床及基础研究。
  2. 承担课题组科研课题以及实验室管理工作,包括财务报销、基础人事、科研项目申报等工作。
  3. 协助PI制定并完成各项教学及科研任务,包括定期安排实验室各项检查、实验室工作汇报、研究生及博士后答辩等。
  4. 维护实验室基本运行,包括实验室仪器设备定期检查、常用药品及耗材及时采购、各项安全措施以及人员资质定期核查等。


  1. 基本薪资面议。
  2. 享受过节费、每月餐补、夏季高温补贴等福利待遇。
  3. 享受住房公积金、基本养老保险、基本医疗保险、失业保险、工伤保险、生育保险。


  1. 个人简历
  2. 学历证明
  3. 发表的SCI文章


Read More

Contact Us

Contact Address

Office Phone


Copyright © 2018 All Rights Reserved.